Bioactivation of loxoprofen to a pharmacologically active metabolite and its disposition kinetics in human skin.

Abstract:

:Loxoprofen (LX) is a prodrug-type non-steroidal anti-inflammatory drug which is used not only as an oral drug but also as a transdermal formulation. As a pharmacologically active metabolite, the trans-alcohol form of LX (trans-OH form) is generated after oral administration to humans. The objectives of this study were to evaluate the generation of the trans-OH form in human in vitro skin and to identify the predominant enzyme for its generation. In the permeation and metabolism study using human in vitro skin, both the permeation of LX and the formation of the trans-OH form increased in a time- and dose-dependent manner after the application of LX gel to the skin. In addition, the characteristics of permeation and metabolism of both LX and the trans-OH form were examined by a mathematical pharmacokinetic model. The Km value was calculated to be 10.3 mm in the human in vitro skin. The predominant enzyme which generates the trans-OH form in human whole skin was identified to be carbonyl reductase 1 (CBR1) by immunodepletion using the anti-human CBR1 antibody. The results of the enzyme kinetic study using the recombinant human CBR1 protein demonstrated that the Km and Vmax values were 7.30 mm and 402 nmol/min/mg protein, respectively. In addition, it was found that no unknown metabolites were generated in the human in vitro skin. This is the first report in which LX is bioactivated to the trans-OH form in human skin by CBR1. Copyright © 2015 John Wiley & Sons, Ltd.

journal_name

Biopharm Drug Dispos

authors

Sawamura R,Sakurai H,Wada N,Nishiya Y,Honda T,Kazui M,Kurihara A,Shinagawa A,Izumi T

doi

10.1002/bdd.1945

subject

Has Abstract

pub_date

2015-09-01 00:00:00

pages

352-363

issue

6

eissn

0142-2782

issn

1099-081X

journal_volume

36

pub_type

杂志文章
  • Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling.

    abstract::Infliximab (IFX) is used as a therapeutic agent for ulcerative colitis (UC) and Crohn's disease (CD). Although the dosage regimen has been established through clinical trial experience, it has yet to be assessed with a pharmacokinetic and pharmacodynamic model. The present study analysed sequential changes of clinical...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2198

    authors: Kimura K,Yoshida A,Katagiri F,Takayanagi R,Yamada Y

    更新日期:2019-07-01 00:00:00

  • Pharmacokinetics of dihydroartemisinin in Artekin tablets for single and repeated dosing in Chinese healthy volunteers.

    abstract::Aim. To study the pharmacokinetics of dihydroartemisinin (DHA) in Artekin (compound dihydroartemisinin) tablets in Chinese healthy volunteers. Methods. Eighteen healthy volunteers (9 males, 9 females) received Artekin tablets for oral administration. The plasma samples of DHA were analysed by liquid-liquid extraction ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章

    doi:10.1002/bdd.607

    authors: Hong X,Liu CH,Huang XT,Huang TL,Ye SM,Ou WP,Wang NS,Mi SQ

    更新日期:2008-05-01 00:00:00

  • Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor.

    abstract:PURPOSE:The chromone derivative MBL-II-141, specifically designed to inhibit ABCG2, was previously demonstrated to combine strong inhibition potency, low toxicity and good efficiency in reversing resistance to irinotecan in a xenografted mouse model. Here, the pharmacokinetic interactions in mice between irinotecan, it...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2069

    authors: Hénin E,Honorat M,Guitton J,Di Pietro A,Payen L,Tod M

    更新日期:2017-07-01 00:00:00

  • Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable?

    abstract::The pharmacokinetic regularity of the murine monoclonal antibody ior EGF/r3 across mammals was studied using allometry. The allometric relationship between the volume of distribution and body weight (W) across mammalian species was characterized by the power equation V(d)=218.8 W(0.84) (r=0.92), and that for clearance...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.398

    authors: Ducongé J,Fernández-Sánchez E,Alvarez D

    更新日期:2004-05-01 00:00:00

  • The lack effect of food on the bioavailability of nefazodone tablets.

    abstract::The objective of this study was to assess the effect of food on the pharmacokinetics of nefazodone (NEF). A group of 24 healthy adult male volunteers received a single 200 mg dose of NEF under fasting conditions as well as 5 min after a high-fat breakfast. There was a 1 week washout between treatments. Serial blood sa...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/(SICI)1099-081X(199603)17:2<135::AID-BDD94

    authors: Dockens RC,Greene DS,Barbhaiya RH

    更新日期:1996-03-01 00:00:00

  • Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects.

    abstract::Dolasetron, Anzemet, a 5-hydroxytryptamine receptor antagonist, is under investigation as an antiemetic agent. The keto-reduced metabolite of dolasetron has been identified in human plasma and is probably responsible for the majority of the antiemetic activity. This study evaluated the pharmacokinetics of dolasetron a...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/bdd.2510160303

    authors: Shah A,Lanman R,Bhargava V,Weir S,Hahne W

    更新日期:1995-04-01 00:00:00

  • Quantification and prediction of skin pharmacokinetics of amoxicillin and cefuroxime.

    abstract::The purpose of this project was to develop and validate a pharmacokinetic model and to quantify the rate and extent of distribution between plasma and skin of two beta-lactam antibiotics, amoxicillin (AMX) and cefuroxime (CFX), which are frequently administered systemically to treat skin and skin structure infections....

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.658

    authors: Shukla C,Patel V,Juluru R,Stagni G

    更新日期:2009-09-01 00:00:00

  • Pharmacokinetics and protein binding of the selective neuronal nitric oxide synthase inhibitor 7-nitroindazole.

    abstract::Utilization of nitric oxide (NO) synthase (NOS) inhibitors to probe the role of NO in various central nervous system processes requires use of an inhibitor selective for neuronal NOS, and is facilitated by knowledge of the pharmacokinetics of the inhibitor. The present project was undertaken to elucidate the dispositi...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.230

    authors: Bush MA,Pollack GM

    更新日期:2000-09-01 00:00:00

  • Specific incorporation of asialofetuin-labeled liposomes into hepatocytes through the action of galactose-binding protein.

    abstract::Asialofetuin-labelled liposomes (AF-liposomes) having mean diameters of 0.13 micron ([S]) and 0.35 micron ([L]) were obtained by the subsequent extrusion method in combination with dialysis. Intravenously administered AF-liposomes [S] were rapidly cleared from the systemic circulation. By pre- and post-treatment of th...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510080404

    authors: Hara T,Aramaki Y,Tsuchiya S,Hosoi K,Okada A

    更新日期:1987-07-01 00:00:00

  • Relative lung and systemic bioavailability of sodium cromoglycate inhaled products using urinary drug excretion post inhalation.

    abstract::The relative lung and systemic bioavailability of sodium cromoglycate following inhalation by different methods have been determined using a urinary excretion pharmacokinetic method. On three separate randomised study days, 7 days apart, subjects inhaled (i) 4x5 mg from an Intal metered dose inhaler (MDI), (ii) 4x5 mg...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/bdd.308

    authors: Aswania O,Chrystyn H

    更新日期:2002-05-01 00:00:00

  • Nonstationary disposition of valproic acid during prolonged intravenous infusion: contributions of unbound clearance and protein binding.

    abstract::Circadian variations in disposition have been observed for a variety of agents, including anticonvulsants. Valproic acid (VPA), an anticonvulsant used to control generalized and partial seizures, has exhibited diurnal oscillations in steady-state concentrations during long-term administration to humans and non-human p...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.259

    authors: Arens TL,Pollack GM

    更新日期:2001-09-01 00:00:00

  • A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymptomatic.

    abstract::The pharmacokinetics of didanosine and ciprofloxacin were evaluated following the administration of multiple oral doses of each drug as a single agent or in combination. Didanosine was dosed as the Videx chewable/dispersible tablet, which contains the antacids dihydroxyaluminum sodium carbonate and magnesium hydroxide...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/(sici)1099-081x(199701)18:1<65::aid-bdd13>

    authors: Knupp CA,Barbhaiya RH

    更新日期:1997-01-01 00:00:00

  • Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits.

    abstract::The effect of the combination of a new anticonvulsant drug HEPP and carbamazepine (CBZ) on the pharmacokinetics of HEPP and CBZ was investigated using rabbits as an animal model. The study was performed in 18 male New Zealand white rabbits which were randomly divided into three groups, according to a balanced incomple...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.356

    authors: García AL,Medina RL,Pérez MR,Jung CH

    更新日期:2003-07-01 00:00:00

  • Characterization of ethiofos absorption in the rat small intestine.

    abstract::The absorption characteristics of ethiofos were studied using the rat in situ intestine circulating perfusion technique. Slow absorption kinetics were observed for ethiofos with varying rates of absorption and metabolism/degradation in situ as a function of buffer and absorption enhancers. In most cases less than 10 p...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510120404

    authors: Geary RS,Swynnerton NF,Timmons SF,Mangold DJ

    更新日期:1991-05-01 00:00:00

  • Partially competitive inhibition of intestinal baclofen absorption by beta-alanine, a nonessential dietary aminoacid.

    abstract::In situ intestinal absorption of baclofen in the rat in the presence of beta-alanine has been investigated. Through the perfusion of 0.50 mM baclofen solutions containing variable concentrations of the aminoacid (from 5 to 100 mM), a partially competitive inhibition of baclofen absorption was characterized: absorption...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510120903

    authors: Polache A,Plá-Delfina JM,Merino M

    更新日期:1991-12-01 00:00:00

  • The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.

    abstract::The effects of gender on the pharmacokinetics of verapamil and its active metabolite, norverapamil, following single oral dose (80 mg, Isoptin) to 12 healthy male (mean age: 25.75+/-2.42 years, mean body weight: 70.59+/-9.94 kg) and 12 healthy female subjects (mean age: 24.08+/-2.84 years, mean body weight: 56.67+/-5....

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章

    doi:10.1002/bdd.512

    authors: Dadashzadeh S,Javadian B,Sadeghian S

    更新日期:2006-10-01 00:00:00

  • Pharmacokinetic interaction of ketoconazole and itraconazole with ciprofloxacin.

    abstract::The effect of the concomitant administration of the antifungal drugs ketoconazole (KTC) and itraconazole (ITC) on the pharmacokinetics of ciprofloxacin (CIP) following short- and long-term administration in mice was investigated. Animals received either a dose of CIP (20 mg/kg, i.p.), CIP (20 mg/kg, i.p.) together wit...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.586

    authors: Abou-Auda HS,Mustafa AA,Al-Humayyd MS

    更新日期:2008-01-01 00:00:00

  • Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24 capsules.

    abstract::In a multiple dose cross-over experiment in 12 healthy male adults the bioavailability and sustained release characteristics of new once daily BY912 400 mg theophylline capsules (= B, Byk Gulden Research Laboratories, FRG) were studied using Theo-24 capsules (= T, Searle & Co., USA) as reference. Both products were gi...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章

    doi:10.1002/bdd.2510100210

    authors: Jonkman JH,Steinijans VW,Beier W,van der Boon WJ,Crasmeijer G

    更新日期:1989-03-01 00:00:00

  • Microcalorimetric investigations of drug-albumin interactions.

    abstract::Flow microcalorimetry was used to estimate primary binding constants for drug-albumin interactions. Measurements of heat of reaction at two temperatures illustrated the danger of extrapolation for pharmacokinetic purposes of measurements made at temperatures other than 37 degrees. The method could be used to predict c...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510050403

    authors: Hardee GH,Fleitman JS,Otagiri M,Perrin JH

    更新日期:1984-10-01 00:00:00

  • Development of oral extended release formulations of 6-hydroxybuspirone.

    abstract::Reducing the maximum plasma concentration whilst maintaining the exposure was shown to ameliorate adverse events following the oral administration of 6-hydroxybuspirone. This observation, along with a desire to provide for once daily dosing of this compound, provided the basis for the development of an extended releas...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/bdd.1819

    authors: Nicholson SJ,Timmins P,Dockens RC,Connor A,Croop R,Ferrie P,Zeng J,Dennis AB,Wilding I

    更新日期:2012-12-01 00:00:00

  • Influence of formulation factors on PpIX production and photodynamic action of novel ALA-loaded microparticles.

    abstract::A novel 5-aminolevulinic acid (ALA)-containing microparticulate system was produced recently, based on incorporation of ALA into particles prepared from a suppository base that maintains drug stability during storage and melts at skin temperature to release its drug payload. The novel particulate system was applied to...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.645

    authors: Donnelly RF,McCarron PA,Al-Kassas R,Juzeniene A,Juzenas P,Iani V,Woolfson AD,Moan J

    更新日期:2009-03-01 00:00:00

  • Toward a quantitative approach for the prediction of the fraction of dose absorbed using the absorption potential concept.

    abstract::An equation based on the absorption potential concept was developed. This enabled us to establish an approach for the quantitative prediction of the fraction of dose absorbed. Classification of drugs into three broad categories, according to their absorption potential values in relation to the fraction of dose absorbe...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510100106

    authors: Macheras PE,Symillides MY

    更新日期:1989-01-01 00:00:00

  • Non-clinical characterization of the disposition of EMA401, a novel small molecule angiotensin II type 2 receptor (AT2R) antagonist.

    abstract::EMA401, (the S-enantiomer of 5-(benzyloxy)-2-(2,2-diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid), also known as Olodanrigan, is an orally active selective angiotensin II type 2 receptor (AT2 R) antagonist that is in Phase IIb clinical development as a novel analgesic for the relief of chro...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2226

    authors: Murgasova R,Carreras ET,Suetterlin-Hachmann M,da Silva Torrao LR,Kittelmann M,Alexandra V,Fredenhagen A

    更新日期:2020-04-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats.

    abstract::The pharmacokinetics and pharmacodynamics of furosemide were investigated after intravenous (i.v.), 1 mg/100 g body weight, and oral administration, 2 mg per 100 g body weight, to spontaneously hypertensive rats (SHRs) and deoxycorticosterone acetate-salt-induced hypertensive rats (DOCA-salt rats). After i.v. administ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510150302

    authors: Jang SH,Lee MG,Kim ND

    更新日期:1994-04-01 00:00:00

  • In vitro and in vivo comparative study of itraconazole bioavailability when formulated in highly soluble self-emulsifying system and in solid dispersion.

    abstract::A semisolid self-emulsifying system (SES) of itraconazole consisting of oleic acid, polysorbate 80 and coajuvant (citric acid) was prepared by a hot-melt technique and then compared with hydroxypropylmethylcellulose (HPMC) solid dispersion (SD) coated onto inert sugar spheres as a reference formulation for in vitro an...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.546

    authors: Park MJ,Ren S,Lee BJ

    更新日期:2007-05-01 00:00:00

  • The bioavailability of oral nifedipine formulations: a statistical and simulation approach.

    abstract::The bioequivalence of three oral forms of nifedipine was assessed in a triple crossover study on 12 healthy volunteers. Single 10 mg dose was given and ten blood samples were drawn during the first 8 h after administration. Highly sensitive gas chromatographic method was used for the nifedipine assay. Pharmacokinetic ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/bdd.2510080104

    authors: Kozjek F,Primozic S,Mrhar A,Karba R,Raemsch KD,Janezic A

    更新日期:1987-01-01 00:00:00

  • Screening of non-steroidal anti-inflammatory drugs for inhibitory effects on the activities of six UDP-glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using LC-MS/MS.

    abstract::Non-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain and to decrease inflammation. Several clinical studies have reported that NSAIDs inhibit uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes. Therefore, the study evaluated the inhibitory potential of 15 NSAIDs on the activities of s...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.1933

    authors: Joo J,Kim YW,Wu Z,Shin JH,Lee B,Shon JC,Lee EY,Phuc NM,Liu KH

    更新日期:2015-05-01 00:00:00

  • Pharmacokinetics and dose linearity testing of methylprednisolone phosphate.

    abstract::The pharmacokinetics of methylprednisolone and methylprednisolone phosphate were investigated after intravenous administration of methylprednisolone phosphate to six healthy subjects at seven different doses between 16 and 1000 mg. Plasma, urine, and saliva were analyzed for methylprednisolone and methylprednisolone p...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章

    doi:10.1002/bdd.2510100504

    authors: Möllmann H,Rohdewald P,Barth J,Verho M,Derendorf H

    更新日期:1989-09-01 00:00:00

  • Simultaneous modelling of mexiletine and hydroxy-methyl-mexiletine data after single- and multiple-dose administration of a sustained-release mexiletine formulation.

    abstract::The pharmacokinetics of mexiletine and its metabolite hydroxy-methyl-mexiletine have been investigated following single-dose and during multiple-dose administration of a sustained-release form of mexiletine to six post-myocardial infarct patients. Comparison of single-dose and washout pharmacokinetics, after short-ter...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510130702

    authors: Bruno R,Santoni Y,Iliadis A,Djiane P,Serradimigni A,Cano JP

    更新日期:1992-10-01 00:00:00

  • The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers.

    abstract::Sildenafil is the first oral therapeutic agent for the management of male erectile dysfunction. Its oral bioavailability is only 40% due to extensive presystemic elimination, mainly by CYP3A4. This study examined the effect of coadministration of ciprofloxacin or clarithromycin, which inhibit CYP3A4, on the bioavailab...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.488

    authors: Hedaya MA,El-Afify DR,El-Maghraby GM

    更新日期:2006-03-01 00:00:00